BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khanna S, Pardi D. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era. Am J Gastroenterol 2020;115:971-4. [PMID: 32618640 DOI: 10.14309/ajg.0000000000000689] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Khanna S, Kraft CS. Fecal Microbiota Transplantation: Tales of Caution. Clin Infect Dis 2021;72:e881-2. [PMID: 32991697 DOI: 10.1093/cid/ciaa1492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Khanna S, Pardi R. Clostridioides difficile infection: curbing a difficult menace. Therap Adv Gastroenterol 2022;15:175628482210899. [DOI: 10.1177/17562848221089906] [Reference Citation Analysis]
3 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
4 Khanna S, Kraft CS. The interplay of SARS-CoV-2 and Clostridioides difficile infection. Future Microbiol 2021;16:439-43. [PMID: 33847139 DOI: 10.2217/fmb-2020-0275] [Reference Citation Analysis]
5 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]
6 Cho YS. Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection. Gut Liver 2021;15:1-2. [PMID: 33443235 DOI: 10.5009/gnl20368] [Reference Citation Analysis]
7 Khanna S. Gut Involvement by COVID-19. Mayo Clin Proc 2020;95:2309-11. [PMID: 33153616 DOI: 10.1016/j.mayocp.2020.09.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Gasmi Benahmed A, Gasmi A, Doşa A, Chirumbolo S, Mujawdiya PK, Aaseth J, Dadar M, Bjørklund G. Association between the gut and oral microbiome with obesity. Anaerobe 2021;70:102248. [PMID: 32805390 DOI: 10.1016/j.anaerobe.2020.102248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Concas G, Barone M, Francavilla R, Cristofori F, Dargenio VN, Giorgio R, Dargenio C, Fanos V, Marcialis MA. Twelve Months with COVID-19: What Gastroenterologists Need to Know. Dig Dis Sci 2021. [PMID: 34333726 DOI: 10.1007/s10620-021-07158-0] [Reference Citation Analysis]
10 Ding X, Yang X, Wang H. Methodology, efficacy and safety of fecal microbiota transplantation in treating inflammatory bowel disease. Medicine in Microecology 2020;6:100028. [DOI: 10.1016/j.medmic.2020.100028] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Khanna S. Advances in Clostridioides difficile therapeutics. Expert Rev Anti Infect Ther 2021;19:1067-70. [PMID: 33427531 DOI: 10.1080/14787210.2021.1874919] [Reference Citation Analysis]
12 Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol 2021;116:647-56. [PMID: 33982930 DOI: 10.14309/ajg.0000000000001075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Khanna S. A defined microbiome therapeutic prevents recurrent Clostridioides difficile. Lancet Gastroenterol Hepatol 2021;6:255-6. [PMID: 33631103 DOI: 10.1016/S2468-1253(21)00011-X] [Reference Citation Analysis]
14 Yeh YM, Cheng HT, Le PH, Chen CC, Kuo CJ, Chen CL, Chiu CT, Chiu CH. Implementation of fecal microbiota transplantation in a medical center for recurrent or refractory Clostridioides difficile infection and report of preliminary outcome. Biomed J 2021:S2319-4170(21)00067-6. [PMID: 34118466 DOI: 10.1016/j.bj.2021.06.001] [Reference Citation Analysis]
15 Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211011953. [PMID: 33995583 DOI: 10.1177/17562848211011953] [Reference Citation Analysis]
16 Ferreira EO, Penna B, Yates EA. Should We Be Worried About Clostridioides difficile During the SARS-CoV2 Pandemic? Front Microbiol 2020;11:581343. [PMID: 33133048 DOI: 10.3389/fmicb.2020.581343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, Park JJ, Shin SY, Lee TH, Choi CH, Cho YS, Yong D, Chung JW, Lee KJ, Lee OY, Choi MG, Choi M; Gut Microbiota and Therapy Research Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil 2022;28:28-42. [PMID: 34980687 DOI: 10.5056/jnm21221] [Reference Citation Analysis]
18 Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc 2021;96:2192-204. [PMID: 34175104 DOI: 10.1016/j.mayocp.2021.03.033] [Reference Citation Analysis]
19 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Khanna S, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi DS. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc 2021;96:1418-25. [PMID: 34088413 DOI: 10.1016/j.mayocp.2021.04.005] [Reference Citation Analysis]